Skip to content
  • Saturday, 12 September 2026
  • 6:34 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Gilead Sciences Pledges Over 400,000 Doses of AmBisome to Combat Visceral Leishmaniasis, Extending Vital Global Health Partnership
Pharmaceutical R&D

Gilead Sciences Pledges Over 400,000 Doses of AmBisome to Combat Visceral Leishmaniasis, Extending Vital Global Health Partnership

Teuku Ryan May 21, 2026 0

Gilead Sciences has announced a significant commitment to global health, pledging over 400,000 doses of its vital antifungal medication, AmBisome…

Read More
Biotech & Genetic Research

A Groundbreaking DNA Test from Hebrew University Revolutionizes Leishmaniasis Tracking and Global Disease Surveillance.

Jia Lissa Mar 20, 2026 0

The Hebrew University of Jerusalem has unveiled a pioneering molecular diagnostic system, spearheaded by researchers at its Koret School of…

Read More
Five Essential Approaches to Robust Outlier Detection in Modern Data AnalysisOptimizing Claude Code Token Usage: Seven Practical Strategies for Cost-Effective AI DevelopmentHow ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platformBrainstem Breakthrough: Researchers Identify Lateral Parafacial Region as Key Driver of Hypertension
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum InformationSolstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy PorustobartScience News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
YOU MAY HAVE MISSED
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026
Pharmaceutical R&D
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Teuku Ryan Sep 12, 2026
Environmental & Analytical Chemistry
Science News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
Abdurrohim Arsyad Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ